{
}
Jefferies has issued a 'Buy' recommendation for Sun Pharma with a target price of ₹2,150 per share, citing potential peak sales of $100 million from its latest cancer treatment assets. Meanwhile, CLSA rates NHPC as 'Outperform', reflecting positive sentiment in the market.Godrej Consumer Products also received a 'Buy' call from Jefferies, targeting ₹1,550 per share, despite anticipated volume declines in soaps and home insecticides. Motilal Oswal has a 'Buy' rating on Reliance Industries, targeting ₹1,580 per share, highlighting strong free cash flow generation and growth prospects in various segments.
UBS anticipates elevated slippages for Micro Finance companies due to a significant rise in overdues, with Portfolio at Risk for zero days increasing by 130 basis points to 17.5% in October. The firm notes that while recent floods may have impacted collection efficiency, the overall delinquency trend suggests ongoing over-leverage issues. UBS maintains a "neutral" rating on several banks with substantial MFI exposure, as tighter disbursement norms are expected to reduce liquidity for weaker borrowers and exacerbate delinquencies in the latter half of the financial year.
In the latest earnings season, Nifty-50 experienced its lowest growth in 17 quarters, with benchmark indices dropping nearly nine percent from their 52-week highs. Motilal Oswal identified ten "winners," including SBI, Sun Pharma, and M&M, which showed resilient performances despite the overall muted results. Conversely, Tata Motors and Asian Paints were highlighted as laggards following disappointing earnings.
Sun Pharma
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Brokerage Recommendations Highlight Buy Calls for Sun Pharma and Godrej Consumer
03:23 09.12.2024
UBS warns of rising slippages in micro finance sector amid overdue surge
13:45 29.11.2024
winners and laggards emerge from muted earnings season in second quarter
09:37 28.11.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: